Illumind therapeutics

Illumind Therapeutics is a Quebec-based neuroscience company dedicated to transforming the treatment of trauma-related neuropsychiatric disorders. The company focuses on developing next-generation therapeutic solutions by utilizing a novel neurobiological model that targets the underlying brain mechanisms associated with glutamate and GABA modulation. By integrating scientific rigor with clinical expertise, Illumind aims to move beyond simple symptomatic alleviation to provide more sustainable and transformative treatments for PTSD and severe anxiety disorders. Drawing on over a decade of fundamental research, the company has transitioned into clinical research, designing trials to reconcile neurobiological data with clinical symptom management. The company collaborates with strategic partners to advance therapeutic standards in mental health, emphasizing a data-driven platform that allows for the dynamic adjustment of clinical parameters to maximize patient benefits and therapeutic impact.